Date(s) - October 14,2022 - October 16,2022
8:00 am - 1:00 pm
Westin Michigan Avenue Chicago
Friday October 14, 2022
Dr. Holmquist is on the Board of Advisors of the American Society of Pain Educators. Over the past decade, he has been invited to present over 1,000 CME and CE lectures on pain management across the country. He shares practical and relevant clinical information, with a touch of humor, ensuring that audiences not only listen but also hear an important message on managing pain and making a difference in the lives of their patients.
1. Discuss the burden of opioid misuse and abuse on the individual and society.
2. Differentiate addiction, physical dependency, tolerance and hyperalgesia.
3. Describe the similarities and differences in the mechanism of action for opioids, cannabinoids, and gabapentenoids.
4. Compare and contrast the role of opioids, cannabinoids, and gabapentenoids in: a) acute postoperative pain; b) chronic low back pain; c) neuropathic pain; d) chronic non-cancer pain; and , e) end-of-life pain crisis.
5. Identify typical characteristics of patients who would be identified as “high risk”, “moderate risk” and “low risk: for misusing, abusing or diverting opioids, and describe the best practice model for properly monitoring patients on opioids.
6. Describe how a provider should counsel patients who are started on opioids, gabapentenoids, and cannabinoids to minimize the risks of adverse reactions, over-dosage and inappropriate compliance.
7. Describe how pharmacists and other providers can improve patient and community safety with the use of opioids, gabapentenoids and cannabinoids.
8. Compare and contrast the most common cannabinoids found in marijuana with regards to their benefits and risks in managing pain and other symptoms.
9. Compare and contrast the benefits and risks of gabapentenoids in managing pain.
10. State the risks of combining opioids with: a) benzodiazepines; b) alcohol; c) gabapentenoids; and, d) cannabinoids.
11. Describe the role of naloxone in preventing deaths from overdosages.
Dr. Stan Louie, Pharm D.
University of Southern California
Dr. Stan Louie received his Doctorate in Pharmacy from the University of California in San Francisco. He continued his postgraduate work at Pacific Presbyterian Medical Center in San Francisco where he was a pharmacy resident. In addition to clinical training, he continued his basic science training at the Kuzell Institute, where he served as Associate of Research in Molecular Biology. Following his training at Kuzell, he joined USC where he continued his work on cytokine regulation in relation to tumor and/or viral proliferation at the Kenneth Norris Cancer Research Institute. Presently, he is an Associate Professor at the University of Southern California School of Pharmacy and the Keck School of Medicine, where he is concentrating his work on virally-linked diseases, which include HIV and hepatitis B & C. In addition, he continues his efforts in drug discovery and development for the treatment of specific brain cancers and multiple myeloma.
Saturday October 15, 2022
1. Explain the risk factors of Hepatitis B & C
2. Develop a pharmaceutical care plan that will effectively manage patients with either Hepatitis B or C infections.
3. Identify the classes of pharmaceutical agents that are active against Hepatitis B or C.
4. Be able to manage drug-induced toxicity associated with the treatment of Hepatitis B or C.
Sunday October 16, 2022
1. Understand how cancer emerges from normal host replication process.
2. Understand how cancer proliferates, progresses and leads to metatastic diseases.
3. Identify conventional agents for various solid tumors (e.g. colon, breast, urologic, and brain cancers).
4. Describe how new kinase inhibitors are able to inhibit cancer progression.
5. Describe how new anti-angiogenesis agents would prevent the progression of cancer proliferation.
6. Understand the types of adverse events that patients may encounter when receiving these types of anti-cancer agents.
7. Be able to convey to patients methods to ameliorate these adverse events.